U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Core binding factor acute myeloid leukemia

MedGen UID:
825586
•Concept ID:
C3839741
•
Neoplastic Process
Synonyms: CBF-AML - core binding factor acute myeloid leukemia; Core Binding Factor Acute Myeloid Leukemia; core binding factor acute myeloid leukemia
SNOMED CT: Core binding factor acute myeloid leukemia (702446006); CBF-AML - core binding factor acute myeloid leukemia (702446006)
 
Monarch Initiative: MONDO:0850269

Definition

Form of acute myeloid leukaemia having a shortage of all types of mature blood cells with onset in childhood or young adulthood. [from SNOMEDCT_US]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVCore binding factor acute myeloid leukemia

Professional guidelines

PubMed

The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment.
Darwish C, Farina K, Tremblay D
Blood Rev 2023 Nov;62:101117. Epub 2023 Jul 25 doi: 10.1016/j.blre.2023.101117. PMID: 37524647
The increasing complexity of the management of core-binding factor acute myeloid leukemia.
Litzow MR
Haematologica 2020 Jun;105(6):1475-1477. doi: 10.3324/haematol.2020.249110. PMID: 32482754Free PMC Article
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.
Mrózek K, Marcucci G, Paschka P, Bloomfield CD
Curr Opin Oncol 2008 Nov;20(6):711-8. doi: 10.1097/CCO.0b013e32831369df. PMID: 18841055Free PMC Article

Recent clinical studies

Etiology

The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment.
Darwish C, Farina K, Tremblay D
Blood Rev 2023 Nov;62:101117. Epub 2023 Jul 25 doi: 10.1016/j.blre.2023.101117. PMID: 37524647
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H
Blood Adv 2020 Jan 14;4(1):66-75. doi: 10.1182/bloodadvances.2019000709. PMID: 31899799Free PMC Article
Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities.
Sinha C, Cunningham LC, Liu PP
Semin Hematol 2015 Jul;52(3):215-22. Epub 2015 Apr 7 doi: 10.1053/j.seminhematol.2015.04.002. PMID: 26111469Free PMC Article
Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.
Duployez N, Willekens C, Marceau-Renaut A, Boudry-Labis E, Preudhomme C
Expert Rev Hematol 2015 Feb;8(1):43-56. Epub 2014 Oct 28 doi: 10.1586/17474086.2014.976551. PMID: 25348871
Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.
Solh M, Yohe S, Weisdorf D, Ustun C
Am J Hematol 2014 Dec;89(12):1121-31. Epub 2014 Aug 27 doi: 10.1002/ajh.23821. PMID: 25088818

Diagnosis

The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment.
Darwish C, Farina K, Tremblay D
Blood Rev 2023 Nov;62:101117. Epub 2023 Jul 25 doi: 10.1016/j.blre.2023.101117. PMID: 37524647
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.
Jahn N, Terzer T, Sträng E, Dolnik A, Cocciardi S, Panina E, Corbacioglu A, Herzig J, Weber D, Schrade A, Götze K, Schröder T, Lübbert M, Wellnitz D, Koller E, Schlenk RF, Gaidzik VI, Paschka P, Rücker FG, Heuser M, Thol F, Ganser A, Benner A, Döhner H, Bullinger L, Döhner K
Blood Adv 2020 Dec 22;4(24):6342-6352. doi: 10.1182/bloodadvances.2020002673. PMID: 33351131Free PMC Article
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H
Blood Adv 2020 Jan 14;4(1):66-75. doi: 10.1182/bloodadvances.2019000709. PMID: 31899799Free PMC Article
Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities.
Sinha C, Cunningham LC, Liu PP
Semin Hematol 2015 Jul;52(3):215-22. Epub 2015 Apr 7 doi: 10.1053/j.seminhematol.2015.04.002. PMID: 26111469Free PMC Article
Core-binding factor acute myeloid leukemia.
Sangle NA, Perkins SL
Arch Pathol Lab Med 2011 Nov;135(11):1504-9. doi: 10.5858/arpa.2010-0482-RS. PMID: 22032582

Therapy

Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.
Duan W, Yang S, Zhao T, Hu L, Qin Y, Jia J, Wang J, Lu S, Jiang H, Zhang X, Xu L, Wang Y, Lai Y, Shi H, Huang X, Jiang Q
Ann Hematol 2023 Oct;102(10):2695-2705. Epub 2023 Aug 12 doi: 10.1007/s00277-023-05400-5. PMID: 37572135
The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment.
Darwish C, Farina K, Tremblay D
Blood Rev 2023 Nov;62:101117. Epub 2023 Jul 25 doi: 10.1016/j.blre.2023.101117. PMID: 37524647
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, Ravandi F, Pemmaraju N, Ohanian M, Daver N, DiNardo C, Alvarado Y, Aldrich J, Borthakur G
Am J Hematol 2022 May;97(5):574-582. Epub 2022 Feb 22 doi: 10.1002/ajh.26496. PMID: 35150150Free PMC Article
Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.
Solh M, Yohe S, Weisdorf D, Ustun C
Am J Hematol 2014 Dec;89(12):1121-31. Epub 2014 Aug 27 doi: 10.1002/ajh.23821. PMID: 25088818
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results.
Bhatt VR, Kantarjian H, Cortes JE, Ravandi F, Borthakur G
Clin Lymphoma Myeloma Leuk 2013 Apr;13(2):153-8. Epub 2012 Dec 21 doi: 10.1016/j.clml.2012.11.006. PMID: 23266036Free PMC Article

Prognosis

The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment.
Darwish C, Farina K, Tremblay D
Blood Rev 2023 Nov;62:101117. Epub 2023 Jul 25 doi: 10.1016/j.blre.2023.101117. PMID: 37524647
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H
Blood Adv 2020 Jan 14;4(1):66-75. doi: 10.1182/bloodadvances.2019000709. PMID: 31899799Free PMC Article
Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities.
Sinha C, Cunningham LC, Liu PP
Semin Hematol 2015 Jul;52(3):215-22. Epub 2015 Apr 7 doi: 10.1053/j.seminhematol.2015.04.002. PMID: 26111469Free PMC Article
Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.
Duployez N, Willekens C, Marceau-Renaut A, Boudry-Labis E, Preudhomme C
Expert Rev Hematol 2015 Feb;8(1):43-56. Epub 2014 Oct 28 doi: 10.1586/17474086.2014.976551. PMID: 25348871
Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.
Solh M, Yohe S, Weisdorf D, Ustun C
Am J Hematol 2014 Dec;89(12):1121-31. Epub 2014 Aug 27 doi: 10.1002/ajh.23821. PMID: 25088818

Clinical prediction guides

Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.
Duan W, Yang S, Zhao T, Hu L, Qin Y, Jia J, Wang J, Lu S, Jiang H, Zhang X, Xu L, Wang Y, Lai Y, Shi H, Huang X, Jiang Q
Ann Hematol 2023 Oct;102(10):2695-2705. Epub 2023 Aug 12 doi: 10.1007/s00277-023-05400-5. PMID: 37572135
Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
Duan W, Liu X, Zhao X, Jia J, Wang J, Gong L, Jiang Q, Zhao T, Wang Y, Zhang X, Xu L, Shi H, Chang Y, Liu K, Huang X, Qin Y, Jiang H
Ann Hematol 2021 May;100(5):1203-1212. Epub 2021 Jan 20 doi: 10.1007/s00277-021-04432-z. PMID: 33474629
Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia.
Khan M, Cortes J, Qiao W, Alzubaidi MA, Pierce SA, Ravandi F, Kantarjian HM, Borthakur G
Clin Lymphoma Myeloma Leuk 2018 Jan;18(1):e19-e25. Epub 2017 Sep 25 doi: 10.1016/j.clml.2017.09.017. PMID: 29107583Free PMC Article
Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?
Chung C, Ma H
Pharmacotherapy 2017 Sep;37(9):1052-1072. Epub 2017 Jul 31 doi: 10.1002/phar.1977. PMID: 28654205
Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, Lapillonne H, Renneville A, Ragu C, Figeac M, Celli-Lebras K, Lacombe C, Micol JB, Abdel-Wahab O, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C
Blood 2016 May 19;127(20):2451-9. Epub 2016 Mar 15 doi: 10.1182/blood-2015-12-688705. PMID: 26980726Free PMC Article

Recent systematic reviews

Prevalence and Clinical Outcome of FMS-Like Tyrosine Kinase Mutations Among Patients With Core Binding Factor-Acute Myeloid Leukemia: Systematic Review and Meta-Analysis.
Srinivasan S, Kumar S, Vijayasekharan K, Agrawal AK
Clin Lymphoma Myeloma Leuk 2022 Apr;22(4):e221-e232. Epub 2021 Oct 2 doi: 10.1016/j.clml.2021.09.020. PMID: 34750085
Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review.
Ayatollahi H, Shajiei A, Sadeghian MH, Sheikhi M, Yazdandoust E, Ghazanfarpour M, Shams SF, Shakeri S
Hematol Oncol Stem Cell Ther 2017 Mar;10(1):1-7. Epub 2016 Sep 3 doi: 10.1016/j.hemonc.2016.08.005. PMID: 27613372
Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
Chen W, Xie H, Wang H, Chen L, Sun Y, Chen Z, Li Q
PLoS One 2016;11(1):e0146614. Epub 2016 Jan 15 doi: 10.1371/journal.pone.0146614. PMID: 26771376Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...